Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects-Reference-Cited by-同舟云学术

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

Published:2013-07-01 Issue:3 Volume:63 Page:346-354
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Cotte Laurent,Dellamonica Pierre,Raffi Francois,Yazdanpanah Yazdan,Molina Jean-Michel,Boué François,Urata Yasuo,Chan H. Phyllis,Zhu Li,Chang Ih,Bertz Richard,Hanna George J.,Grasela Dennis M.,Hwang Carey

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference14 articles.

1. . Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.;Hetherington;Clin Ther,2001

2. . Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.;Islam;HIV Med,2012

3. . Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.;Patel;Antivir Ther,2012

4. . Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.;Bedimo;AIDS,2012

5. . Association of tenofovir exposure with kidney disease risk in HIV infection.;Scherzer;AIDS,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved;Bioorganic & Medicinal Chemistry;2024-09

2. 4′-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives;Accounts of Chemical Research;2022-01-25

3. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial;Trials;2021-03-09

4. Enantioselective organocatalytic approaches to active pharmaceutical ingredients – selected industrial examples;Physical Sciences Reviews;2019-05-29

5. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial;The Lancet HIV;2016-01